pcsk9 loss-of-function mutations
DESCRIPTION
PCSK9 Loss-of-function Mutations. PCSK9-Mediated Degradation of LDL-R. Evolution of Therapeutic Monoclonal Antibodies. Effect of PCSK9 Inhibitors on LDL-C in Heterozygous FH. DESCARTES % Change in LDL-C From Baseline at Week 52 in Patients With Hypercholesterolemia. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: PCSK9 Loss-of-function Mutations](https://reader036.vdocument.in/reader036/viewer/2022062308/56812cd1550346895d918b80/html5/thumbnails/1.jpg)
![Page 2: PCSK9 Loss-of-function Mutations](https://reader036.vdocument.in/reader036/viewer/2022062308/56812cd1550346895d918b80/html5/thumbnails/2.jpg)
![Page 3: PCSK9 Loss-of-function Mutations](https://reader036.vdocument.in/reader036/viewer/2022062308/56812cd1550346895d918b80/html5/thumbnails/3.jpg)
PCSK9 Loss-of-function Mutations
![Page 4: PCSK9 Loss-of-function Mutations](https://reader036.vdocument.in/reader036/viewer/2022062308/56812cd1550346895d918b80/html5/thumbnails/4.jpg)
PCSK9-Mediated Degradation of LDL-R
![Page 5: PCSK9 Loss-of-function Mutations](https://reader036.vdocument.in/reader036/viewer/2022062308/56812cd1550346895d918b80/html5/thumbnails/5.jpg)
Evolution of Therapeutic Monoclonal Antibodies
![Page 6: PCSK9 Loss-of-function Mutations](https://reader036.vdocument.in/reader036/viewer/2022062308/56812cd1550346895d918b80/html5/thumbnails/6.jpg)
![Page 7: PCSK9 Loss-of-function Mutations](https://reader036.vdocument.in/reader036/viewer/2022062308/56812cd1550346895d918b80/html5/thumbnails/7.jpg)
Effect of PCSK9 Inhibitors on LDL-C in Heterozygous FH
![Page 8: PCSK9 Loss-of-function Mutations](https://reader036.vdocument.in/reader036/viewer/2022062308/56812cd1550346895d918b80/html5/thumbnails/8.jpg)
DESCARTES% Change in LDL-C From Baseline at Week 52 in Patients With
Hypercholesterolemia
![Page 9: PCSK9 Loss-of-function Mutations](https://reader036.vdocument.in/reader036/viewer/2022062308/56812cd1550346895d918b80/html5/thumbnails/9.jpg)
GAUSS-1% Change in LDL-C From Baseline at Week 12 in Statin-Intolerant Patients
![Page 10: PCSK9 Loss-of-function Mutations](https://reader036.vdocument.in/reader036/viewer/2022062308/56812cd1550346895d918b80/html5/thumbnails/10.jpg)
Effect of PCSK9 Monoclonal Antibodies on ApoB and Lp(a)
![Page 11: PCSK9 Loss-of-function Mutations](https://reader036.vdocument.in/reader036/viewer/2022062308/56812cd1550346895d918b80/html5/thumbnails/11.jpg)
Role of apoB
![Page 12: PCSK9 Loss-of-function Mutations](https://reader036.vdocument.in/reader036/viewer/2022062308/56812cd1550346895d918b80/html5/thumbnails/12.jpg)
How Low Is Too Low?
![Page 13: PCSK9 Loss-of-function Mutations](https://reader036.vdocument.in/reader036/viewer/2022062308/56812cd1550346895d918b80/html5/thumbnails/13.jpg)
PCSK9 CV Outcomes Trials
![Page 14: PCSK9 Loss-of-function Mutations](https://reader036.vdocument.in/reader036/viewer/2022062308/56812cd1550346895d918b80/html5/thumbnails/14.jpg)
TESLATrial Evaluating PCSK9 Antibody in Homozygous FH
![Page 15: PCSK9 Loss-of-function Mutations](https://reader036.vdocument.in/reader036/viewer/2022062308/56812cd1550346895d918b80/html5/thumbnails/15.jpg)
Abbreviations
![Page 16: PCSK9 Loss-of-function Mutations](https://reader036.vdocument.in/reader036/viewer/2022062308/56812cd1550346895d918b80/html5/thumbnails/16.jpg)
Abbreviations (cont)
![Page 17: PCSK9 Loss-of-function Mutations](https://reader036.vdocument.in/reader036/viewer/2022062308/56812cd1550346895d918b80/html5/thumbnails/17.jpg)
References
![Page 18: PCSK9 Loss-of-function Mutations](https://reader036.vdocument.in/reader036/viewer/2022062308/56812cd1550346895d918b80/html5/thumbnails/18.jpg)
References (cont)
![Page 19: PCSK9 Loss-of-function Mutations](https://reader036.vdocument.in/reader036/viewer/2022062308/56812cd1550346895d918b80/html5/thumbnails/19.jpg)
References (cont)